Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001507663 | SCV001713349 | uncertain significance | not provided | 2021-01-26 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002506587 | SCV002797597 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2021-07-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002506587 | SCV003246754 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2022-07-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1010 of the ADAMTS2 protein (p.Gly1010Ser). This variant is present in population databases (rs368690576, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with ADAMTS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1162984). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |